Alzheimer risk-increasing TREM2 variant causes aberrant cortical synapse density and promotes network hyperexcitability in mouse models
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2) increases the risk of Alzheimer's disease (AD). To investigate potential mechanisms, we analyzed knockin mice expressing human TREM2-R47H from one mutant mouse Trem2 allele. TREM2-R47H mice showed increased seizure activity in response to an acute excitotoxin challenge, compared to wildtype controls or knockin mice expressing the common variant of human TREM2. TREM2-R47H also increased spontaneous thalamocortical epileptiform activity in App knockin mice expressing amyloid precursor proteins bearing autosomal dominant AD mutations and a humanized amyloid-β sequence. In mice with or without such App modifications, TREM2-R47H increased the density of putative synapses in cortical regions without amyloid plaques. TREM2-R47H did not affect synaptic density in hippocampal regions with or without plaques. We conclude that TREM2-R47H increases AD-related network hyperexcitability and that it may do so, at least in part, by causing an imbalance in synaptic densities across brain regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“, 2014), in which both mouse App alleles have a humanized Aβ sequence and carry the Swedish (KM to NL), Arctic (E to G), and Iberian (I to F) mutations that cause autosomal dominant AD in humans (Mullan et al., 1992; Nilsberth et al., 2001; Guerreiro et al., 2010), were obtained from Drs.”
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 5×
“To determine whether TREM2 also exacerbates epileptiform activity caused by chronic expression of FAD-mutant APP/A, we crossed TREM2 mice onto a homozygous App background (Saito et al., 2014).”
InfluentialAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“typically cause early-onset AD with a high degree of penetrance, whereas R47H-variant TREM2 increases the relative risk of developing AD of later onset by ≤4-fold (Guerreiro et al., 2013; Jonsson et al., 2013; Karch and Goate, 2015; Jay et al., 2017; Song et al., 2017; Ulrich et al., 2017; Ulland and Colonna, 2018; Be…”
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 1×
“…and carry the Swedish (KM to NL), Arctic (E to G), and Iberian (I to F) mutations that cause autosomal dominant AD in humans (Mullan et al., 1992; Nilsberth et al., 2001; Guerreiro et al., 2010), were obtained from Drs. Takashi Saito and Takaomi Saido (RIKEN); for brevity, these mice are…”
Negative feedback control of neuronal activity by microglia
Badimon, A., Strasburger, H. J., Ayata, P., Chen, X., Nair, A., Ikegami, A., Hwang, P., Chan, A. T., Graves, S. M., Uweru, J. O., et al. (2020) · Nature · doi:10.1038/s41586-020-2777-8 · Cited by 979
The ageing cortical synapse: hallmarks and implications for cognitive decline
Morrison, J. H., & Baxter, M. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3200 · Cited by 965
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
TREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 10×
“A prominent example is the triggering receptor expressed on myeloid cells 2 (TREM2), which belongs to the immunoglobulin superfamily and, in the brain, is expressed primarily by microglia (Jay et al., 2017; Ulland and Colonna, 2018; Deczkowska et al., 2020).”
InfluentialFilipello, F., Morini, R., Corradini, I., Zerbi, V., Canzi, A., Michalski, B., Erreni, M., Markicevic, M., Starvaggi-Cucuzza, C., Otero, K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.016 · Cited by 695
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 1×
“Homozygous mutations that inactivate TREM2 cause Nasu-Hakola disease, which combines early-onset dementia with epilepsy and other abnormalities (Paloneva et al., 2002; Bianchin et al., 2004; Kaneko et al., 2010; Nakamagoe et al., 2011; Jay et al., 2017).”
The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway
Deczkowska, A., Weiner, A., & Amit, I. (2020) · Cell · doi:10.1016/j.cell.2020.05.003 · Cited by 648
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
Self-citationMicroglia mediate forgetting via complement-dependent synaptic elimination
Wang, C., Yue, H., Hu, Z., Shen, Y., Ma, J., Li, J., Wang, X.-D., Wang, L., Sun, B., Shi, P., et al. (2020) · Science · doi:10.1126/science.aaz2288 · Cited by 629
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587 · cited 1×
“…AD, TREM2 and microglia likely have direct and indirect interactions with additional pathogenic factors besides those investigated in the current study, including with tau and apolipoprotein E4 (Atagi et al., 2015; Yeh et al., 2016; Shi and Holtzman, 2018; Gratuze et al., 2020; Sayed et al., 2021).”
Eyo, U. B., Peng, J., Swiatkowski, P., Mukherjee, A., Bispo, A., & Wu, L.-J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0416-14.2014 · Cited by 509
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Lee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396 · cited 4×
“…that enhancing TREM2 activity could be of therapeutic benefit in AD and other dementias associated with hypofunction of TREM2 (Zheng et al., 2017; Lee et al., 2018; Lewcock et al., 2020; Schlepckow et al., 2020; Ferrara et al., 2022), and extend this concept to the suppression of network…”
InfluentialEnhanced synaptic connectivity and epilepsy in C1q knockout mice
Chu, Y., Jin, X., Parada, I., Pesic, A., Stevens, B., Barres, B., & Prince, D. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913449107 · Cited by 364
The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit
Shih, A. Y., Blinder, P., Tsai, P. S., Friedman, B., Stanley, G., Lyden, P. D., & Kleinfeld, D. (2013) · Nature Neuroscience · doi:10.1038/nn.3278 · Cited by 351
Elucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region
Schlepckow, K., Monroe, K. M., Kleinberger, G., Cantuti‐Castelvetri, L., Parhizkar, S., Xia, D., Willem, M., Werner, G., Pettkus, N., Brunner, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911227 · Cited by 324 · cited 1×
“Like humans with AD, mouse models with cerebral accumulation of human amyloid-β (Aβ) have increased microglial expression of TREM2 (Melchior et al., 2010; Matarin et al., 2015; Zhou et al., 2020; Das et al., 2021; Schoch et al., 2021; Xia et al., 2022).”
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
Jacobs, H. I. L., Van Boxtel, M. P. J., Jolles, J., Verhey, F. R. J., & Uylings, H. B. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.009 · Cited by 293
Matarin, M., Salih, D. A., Yasvoina, M., Cummings, D. M., Guelfi, S., Liu, W., Nahaboo Solim, M. A., Moens, T. G., Paublete, R. M., Ali, S. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.041 · Cited by 290
The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0262-8 · Cited by 252 · cited 1×
“This conclusion is consistent with other lines of evidence supporting a hypofunction mechanism of TREM2 variants that increase the risk of AD or other dementias (Cheng-Hathaway et al., 2018; Sudom et al., 2018).”
Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration
Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
Early neuronal accumulation of DNA double strand breaks in Alzheimer’s disease
Shanbhag, N. M., Evans, M. D., Mao, W., Nana, A. L., Seeley, W. W., Adame, A., Rissman, R. A., Masliah, E., & Mucke, L. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0723-5 · Cited by 214
Self-citationAssociation of epileptiform abnormalities and seizures in Alzheimer disease.
Lam, A. D., Sarkis, R. A., Pellerin, K. R., Jing, J., Dworetzky, B. A., Hoch, D. B., Jacobs, C. S., Lee, J. W., Weisholtz, D. S., Zepeda, R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010612 · Cited by 172 · cited 4×
“However, a substantial proportion of patients with sporadic AD have “subclinical” nonconvulsive epileptiform activity, which occurs most frequently during sleep (Vossel et al., 2016; Horváth et al., 2017; Lam et al., 2020).”
InfluentialAD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation
Sayed, F. A., Kodama, L., Fan, L., Carling, G. K., Udeochu, J. C., Le, D., Li, Q., Zhou, L., Wong, M. Y., Horowitz, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe3947 · Cited by 155
Self-citationSudom, A., Talreja, S., Danao, J., Bragg, E., Kegel, R., Min, X., Richardson, J., Zhang, Z., Sharkov, N., Marcora, E., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002352 · Cited by 149
Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145 · cited 2×
“…epileptiform activity (Vossel et al., 2016; Horváth et al., 2017; Lam et al., 2017; Lam et al., 2020), excitotoxicity-causing microinfarcts (Shih et al., 2013; Kalaria and Sepulveda-Falla, 2021), and the abnormal accumulation of APP metabolites (Multhaup et al., 2015; Haass and Selkoe, 2022).”
Horvath, A. A., Papp, A., Zsuffa, J., Szucs, A., Luckl, J., Radai, F., Nagy, F., Hidasi, Z., Csukly, G., Barcs, G., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.03.050 · Cited by 125
Xia, D., Lianoglou, S., Sandmann, T., Calvert, M., Suh, J. H., Thomsen, E., Dugas, J., Pizzo, M. E., DeVos, S. L., Earr, T. K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00547-7 · Cited by 124
Whitesell, J. D., Buckley, A. R., Knox, J. E., Kuan, L., Graddis, N., Pelos, A., Mukora, A., Wakeman, W., Bohn, P., Ho, A., et al. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24555 · Cited by 99
Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
Schoch, K. M., Ezerskiy, L. A., Morhaus, M. M., Bannon, R. N., Sauerbeck, A. D., Shabsovich, M., Jafar-nejad, P., Rigo, F., & Miller, T. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100356118 · Cited by 78
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73 · cited 4×
“spikes but more spike-and-wave discharges (SWDs) (Johnson et al., 2020).”
InfluentialSelf-citationRen, S., Yao, W., Tambini, M. D., Yin, T., Norris, K. A., & D'Adamio, L. (2020) · eLife · doi:10.7554/elife.57513 · Cited by 68
Assessment of the Genetic Architecture of Alzheimer’s Disease Risk in Rate of Memory Decline
Del-Aguila, J. L., Fernández, M. V., Schindler, S., Ibanez, L., Deming, Y., Ma, S., Saef, B., Black, K., Budde, J., Norton, J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170834 · Cited by 60 · cited 2×
“this type of network dysfunction could contribute to the accelerated cognitive decline that has been observed in R47H carriers (Del-Aguila et al., 2018).”
Onos, K. D., Quinney, S. K., Jones, D. R., Masters, A. R., Pandey, R., Keezer, K. J., Biesdorf, C., Metzger, I. F., Meyers, J. A., Peters, J., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12329 · Cited by 16
Cited by
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
“Another important consideration is that micro-glial cell-mediated synapse elimination may not always be detrimental in neurodegeneration 570,571 .”
Yang, G., Xu, X., Gao, W., Wang, X., Zhao, Y., & Xu, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1700692 · Cited by 85
Microglia phagocytic mechanisms: Development informing disease
Beiter, R. M., Sheehan, P. W., & Schafer, D. P. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102877 · Cited by 44
TREM2 risk variants and associated endophenotypes in alzheimer’s disease
Dijkstra, J. I. R., Vermunt, L., Venkatraghavan, V., Ozhegov, G., Coomans, E. M., Ossenkoppele, R., van de Giessen, E., Hulsman, M., de Geus, C. M., van der Flier, W. M., et al. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01700-2 · Cited by 18
Metadata
- Authors
- Das, M., Mao, W., Voskobiynyk, Y., Necula, D., Lew, I., Petersen, C., Zahn, A., Yu, G.-Q., Yu, X., Smith, N., Sayed, F. A., Gan, L., Paz, J. T., & Mucke, L.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 186
- Pages
- 106263
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W4385830484
- Cited by
- 41
- References
- 43
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.